navitoclax

Navitoclax is an orally bioavailable small molecule inhibitor that targets anti-apoptotic Bcl-2 family proteins, including Bcl-2, Bcl-xL, and Bcl-w. These proteins are often overexpressed in various cancers such as lymphomas, breast cancer, lung cancer, prostate cancer, and colon cancer and are associated with tumor drug resistance[1][2][5]. By binding to these proteins with high affinity and inhibiting their function, navitoclax disrupts their ability to prevent apoptosis (programmed cell death), thereby promoting the death of cancer cells[6]. Navitoclax has been investigated for its pro-apoptotic effects in hematological malignancies (such as chronic lymphocytic leukemia) and solid tumors. It also exhibits senolytic activity by selectively inducing apoptosis in senescent cells without affecting non-senescent cells[5]. The drug is being developed primarily by AbbVie for oncological indications including myelofibrosis and other cancers[7].

Other names

ABT-263ABT263ABT 263